How much revenue does Shouyao Holdings (Beijing) make?

Shouyao Holdings (Beijing) reported 8.67 million CNY in revenue for fiscal year 2025, up 119.9% from 3.94 million CNY in fiscal year 2024. In Q1 2026 revenue was 28.00 million CNY.

What companies are similar to Shouyao Holdings (Beijing)?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS), Jiangsu Yahong Meditech Co., Ltd. (688176.SS), Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SS), Hinova Pharmaceuticals Inc. (688302.SS).

Shouyao Holdings (Beijing) Co., Ltd. (688197.SS) Stock

About Shouyao Holdings (Beijing) Co., Ltd.

Shouyao Holdings (Beijing) Co., LTD. engages in the research, development, and production of drugs in China. The company offers drugs for oncology indications, including non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, breast cancer, ovarian cancer, thyroid cancer, leukemia, and diabetes. The company was founded in 2016 and is headquartered in Beijing, China.

At a glance

Shouyao Holdings (Beijing) reported revenue of 8.67 million CNY for fiscal year 2025, up 119.9% from fiscal year 2024, and net income of -128.83 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 28.00 million CNY, up 1300.0% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.